

Table 3 Changes of clinical data between pre- and post-GS therapy.

Variables	GS group (n = 39)
Reduction rate (%)	
CEA	-15.4 (-145.5–71.1)
CA19-9	39.9 (-108.2–94)
Dupan-2	36.2 (-41.7–84.9)
Span-1	40.7 (-100–82.5)
Elastase-1	29.2 (-220–98.6)
Tumor size	19 (-16–46.5)
Radiographic response (CR/PR/SD/PD)	0/6/33/0
ARDI (%)	90.8 (39.3–100)
Body weight loss (kg)	1.9 (-3–15.1)

Data are expressed as median (range)

ARDI average relative dose intensity, *CA19-9* carbohydrate antigen 19-9, *CEA* carcinoembryonic antigen, *CR* complete response, *Dupan-2* pancreatic cancer associated antigen, *GS* gemcitabine plus S-1, *NAC* neoadjuvant chemotherapy, *PD* progressive disease, *PR* partial response, *SD* stable disease, *Span-1* S-pancreas-1.